fig3

Figure 3. ImmuneScore as a prognostic indicator of PFS in patients with non-squamous NSCLC receiving ICI therapy combined with chemotherapy. (A) ImmuneScore could predict median PFS, with higher AUC than that of PD-L1 TPS; (B) Patients with high ImmuneScore had longer PFS than those with low ImmuneScore; (C) Higher ImmuneScore indicated longer PFS in PD-L1 TPS ≥ 1% and PD-L1 TPS < 1% subgroups; (D) Higher ImmuneScore indicated longer PFS in PD-L1 TPS ≥ 50% and PD-L1 TPS < 50% subgroups. NSCLC: Non-squamous cell lung cancer; ICI: immune checkpoint inhibitor; PFS: progression-free survival; PD-L1 TPS: programmed cell death 1 ligand 1 tumor proportion score; AUC: area under the ROC curve; IS: ImmuneScore; HR: hazard ratio.